中文摘要：

目的：HER2（human EGF receptor type 2）在食管癌中的过表达是否与食管癌患者生存期缩短相关,存在着两种不同的观点。为此,我们在大样本回顾性调查基础上,做进一步的研究,为弄清两者是否相关提供有用的数据资料。方法：在收集1988~1997年间的341例食管癌病例进行回顾性调查的基础上,通过联合应用组织芯片和免疫组织化学等实验方法检测食管癌组织中HER2的表达,分析HER2表达与食管癌患者生存期之间的相关性。结果：与正常食管上皮组织相比,HER2在多数食管癌组织中过表达;HER2过表达与食管癌组织细胞的分化程度相关（P〈0.05）;但与食管癌患者生存期缩短相关性不明显（P〉0.05）。结论：按FDA判定标准,食管癌组织细胞中HER2蛋白的过表达不是判定食管癌患者生存期缩短的有效指标。

英文摘要：

OBJECTIVE：There are two opposite views in whether the over-expression of HER2（human EGF receptor type 2） in esophageal carcinoma is associated with the short survival time of the patients. So, we did a further big study to provide some useful data. METHODS： The expression of HER2 in 341 specimens of esophageal carcinoma was detected by making tissue chips and using immunohistochemistry. The correlation between HER2 expression and the survival time of patients was estimated using the Kaplan-Meier method based on a retrospective study of ten years. RESULTS： The HER2 protein was over-expressed in most esophageal carcinoma tissues compared to normal esophageal epithelium. There is a correlation between the over-expression of HER2 and the differentiation of the carcinoma. The over-expression of HER2 in carcinoma was not associated with short survival time. CONCLUSION： Using the FDA scoring system, over-expression of HER2 protein was not a significant factor for poor prognosis of esophageal carcinoma patients.